Harleysville, PA, United States of America

Mark E Layton

This inventor holds 32 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 17 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Msd K.k.. Active years: 1993-2026.

USPTO Granted Patents = 32 (Patent Applications = 16)

% Patents Active = 87.5

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 17 (Patent Applications = 32)

Average Co-Inventor Count = 5.4

ph-index = 6

Forward Citations = 136(Granted Patents)

Location History:

Orem, UT (US) (1993)
West Point, PA (US) (2017)
Harleysville, PA (US) (2008 - 2023)

Company Filing History:

25 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

patents

5. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2026

Loading Chart...

Areas of Expertise:

NAV1.8 Inhibitors

Voltage-Gated Sodium Channels

Positive Allosteric Modulators

AKT Inhibitors

Benzothiazolones

Pyrimidine PDE10 Inhibitors

Imidazopyridin Derivatives

Cancer Therapy

Aryl Sulfonamide Compounds

Diamino-Alkylamino Compounds

Hydroxypyrrolidine Compounds

Bicycloamine Compounds

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723035 - Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as Nav1.8 inhibitors (2026-09-01),

2. 12516046 - 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors (2026-01-06),

3. 12427159 - Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels (2025-09-30),

4. 12344595 - 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors (2025-07-01),

5. 12246008 - 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels (2025-03-11),

6. 12195445 - 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors (2025-01-14),

7. 11802122 - 2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors (2023-10-31),

8. 11377438 - 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors (2022-07-05),

9. 10968210 - Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels (2021-04-06),

10. 10519147 - Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels (2019-12-31),

11. 10442778 - N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels (2019-10-15),

12. 9624208 - Benzoxazolinone compounds with selective activity in voltage-gated sodium channels (2017-04-18),

13. 9586968 - Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels (2017-03-07),

14. 9388179 - N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels (2016-07-12),

15. 9315518 - Imidazopyridin-2-one derivatives (2016-04-19),

Title: The Innovations of Mark E. Layton: A Patented Legacy

Introduction

Mark E. Layton, based in Harleysville, PA, has made significant strides in the field of pharmaceuticals, amassing a remarkable portfolio of 26 patents. His work primarily focuses on compounds that have the potential to revolutionize the treatment of various pain and cough disorders through innovative channel activity inhibition.

Latest Patents

Among his latest contributions to science are two notable patents. The first is for "2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors." This invention presents novel compounds that inhibit Na1.8 channel activity. These compounds hold promise in treating, preventing, and managing diseases linked to Na1.8 channel activity, specifically addressing pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

The second patent, "2-oxoimidazolidine-4-carboxamides as Na1.8 inhibitors," echoes similar innovative themes. These compounds are designed to inhibit Na1.8 channel activity, paving the way for advancements in managing various disorders, including those related to pain and itch.

Career Highlights

Throughout his career, Mark E. Layton has collaborated with prestigious companies renowned for their impactful research and development, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. His tenure at these organizations has cultivated an environment of innovation and research excellence, allowing him to contribute significantly to the pharmaceutical landscape.

Collaborations

Mark's collaborative spirit shines through his partnerships with esteemed colleagues, such as Michael J. Kelly, III, and Philip E. Sanderson. Their combined expertise has led to groundbreaking developments in their field, which have further solidified their reputation for pioneering work in pharmaceuticals.

Conclusion

Mark E. Layton's body of work encapsulates a dedication to innovation in the treatment of critical health issues. His 26 patents, particularly in developing Na1.8 channel inhibitors, demonstrate his commitment to enhancing therapeutic options for patients facing various disorders. As the pharmaceutical industry continues to evolve, Layton's contributions will likely inspire future advancements in medical research and innovation.